RecruitingDepression in Adolescence

Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep to Reward- and Stress-Related Brain Function

Eligible age

14–18 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This research will use biobehavioral approaches to generate understanding about the linkages between sleep duration and timing, stressful life events, and depressive symptoms in adolescents, with a long-term aim of developing effective preventative interventions.

Sponsor: University of Oregon

You may qualify if…

✓ 1. 14-18 years of age
✓ 2. Currently in high school
✓ 3. short and late sleep (weekday sleep duration ≤ 7 h and bedtime ≥ 22:30 (10:30 pm); n=100) or long and early sleep (weekday sleep duration \> 7 hours and bedtime ≤ 22:30 (10:30 pm); n=50), indexed by the Munich Chronotype Questionnaire
✓ 4. Lifetime stressful event frequency ≥ 2 on the Stress and Adversity Inventory (STRAIN) Screener
✓ 5. Depressive symptom severity t-score greater than or equal to 45 on the Patient Reported Outcomes (PROMIS) Depression scale
✓ 6. English language fluency

You may not qualify if…

✕ 1. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for current moderate to severe alcohol/substance use disorder (≥4 symptoms);
✕ 2. Current clinician-provided diagnosis of narcolepsy or idiopathic hypersomnia;
✕ 3. Lifetime diagnosis of bipolar or schizophrenia spectrum disorder;
✕ 4. Certain medical conditions (e.g., serious neurological disorder, heart failure or serious heart trouble, history of head injury with unconsciousness \> 5 minutes);
✕ 5. Conditions that are contraindicated for magnetic resonance imaging (MRI; e.g., ferrous metal in the body);
✕ 6. Positive screen for participant-reported eye disease, epilepsy, or photosensitizing medications that are contraindicated during the manipulation condition when bright light is administered (e.g., psychiatric neuroleptic drugs \[e.g., phenothiazine\], psoralen drugs, antiarrhythmic drugs \[e.g., amiodarone\], antimalarial and antirheumatic drugs, porphyrin drugs used in photodynamic treatment of skin diseases);
✕ 7. Use of melatonin if participant is not willing to discontinue use for the duration of the study.
✕ We will schedule around (i.e., delay appointments as needed) to avoid the timeframe of the following events:

Where it's recruiting

Oregon

Eugene

Source: ClinicalTrials.gov · NCT05691439 · last updated 2025-11-17